Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report
Case Reports in Ophthalmological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crop/1200325 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Ophthalmological Medicine, online erschienen am 17.04.2026. Verfasst von Mahdi Nemati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Retina & Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Everolimus, an antineoplastic drug, is associated with various systemic adverse effects. This case report is aimed at presenting a novel ophthalmological complication, drug‐associated central serous chorioretinopathy (CSCR), following everolimus administration.
Methods
A 54‐year‐old male with metastatic renal cell carcinoma presented with blurred vision and metamorphopsia. Comprehensive ophthalmologic examination, including multimodal imaging with optical coherence tomography (OCT), fluorescein angiography (FA), and fundus autofluorescence (FAF), was performed. A thorough review of his medical history and recent medication changes was conducted to identify potential associating factors.
Results
Multimodal imaging confirmed bilateral CSCR with subretinal fluid and pachychoroid features. The only recent change in his medication regimen was the initiation of everolimus (10 mg daily) 1 month prior to symptom onset. All other known risk factors for CSCR, such as corticosteroid use, were absent. Upon discontinuation of everolimus, the patient′s symptoms and visual acuity improved. Follow‐up OCT imaging demonstrated complete resolution of the subretinal fluid.
Conclusion
Everolimus can potentially be a risk factor for subclinical CSCR deterioration in prone population. Ophthalmologists and oncologists should be aware of this rare but significant adverse effect.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Retina & Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.
ORCID-Profile: Mohammadreza Niyousha, Narges Hassanpoor
Zitieren
APA
Nemati, M., Niyousha, M., Kharazi, B., & Hassanpoor, N. (2026). Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report. Case Reports in Ophthalmological Medicine, 2026(1). https://doi.org/10.1155/crop/1200325
Vancouver
Nemati M, Niyousha M, Kharazi B, Hassanpoor N. Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report. Case Reports in Ophthalmological Medicine. 2026;2026(1). doi:10.1155/crop/1200325
BibTeX
@article{Nemati2026,
author = {Nemati, Mahdi and Niyousha, Mohammadreza and Kharazi, Banafshe and Hassanpoor, Narges},
title = {Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report},
journal = {Case Reports in Ophthalmological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crop/1200325}
}
EUVIMED